BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma

BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma

Abstract Bromodomain-containing protein 9 (BRD9), an essential component of the SWI/SNF chromatin remodeling complex termed ncBAF, has been established as a therapeutic target in a subset of sarcomas and leukemias. Here, we used novel small molecule inhibitors and degraders along with RNA interferen...

Full description

Bibliographic Details
Main Authors: Ellen Weisberg, Basudev Chowdhury, Chengcheng Meng, Abigail E. Case, Wei Ni, Swati Garg, Martin Sattler, Abdel Kareem Azab, Jennifer Sun, Barbara Muz, Dana Sanchez, Anthia Toure, Richard M. Stone, Ilene Galinsky, Eric Winer, Scott Gleim, Sofia Gkountela, Alexia Kedves, Edmund Harrington, Tinya Abrams, Thomas Zoller, Andrea Vaupel, Paul Manley, Michael Faller, BoYee Chung, Xin Chen, Philipp Busenhart, Christine Stephan, Keith Calkins, Debora Bonenfant, Claudio R. Thoma, William Forrester, James D. Griffin
Format: Article
Language:English
Published: Nature Publishing Group 2022-07-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-022-00704-7

Internet

https://doi.org/10.1038/s41408-022-00704-7

Similar Items